Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality.
In Vivo
; 34(5): 3027-3028, 2020.
Artículo
en Inglés
| MEDLINE | ID: covidwho-740632
ABSTRACT
The FDA-approved drugs raloxifene and bazedoxifene could be among the best candidates to prevent mortality in severe COVID-19 patients. Raloxifene and bazedoxifene inhibit IL-6 signaling at therapeutic doses, suggesting they have the potential to prevent the cytokine storm, ARDS and mortality in severe COVID-19 patients, as is being shown with humanized antibodies blocking IL-6 signaling. In addition, raloxifene and bazedoxifene are selective estrogen receptor modulators with strong antiviral activity.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Neumonía Viral
/
Síndrome de Dificultad Respiratoria
/
Infecciones por Coronavirus
/
Clorhidrato de Raloxifeno
/
Indoles
Tipo de estudio:
Estudio pronóstico
Límite:
Humanos
Idioma:
Inglés
Revista:
In Vivo
Asunto de la revista:
Neoplasmas
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS